

Vitamin A notches up CD11b^{hi} dendritic cell development

Angus T. Stock and Sammy Bedoui

Department of Microbiology and Immunology, The University of Melbourne

Melbourne, Victoria, Australia; FAX: +61-3-93471540

Keywords: Dendritic cells, Developmental immunology, Spleen

Correspondence: astock@unimelb.edu.au or sbedoui@unimelb.edu.au

See accompanying article by Beijer et al.

Received: April 18, 2013; Revised: April 18, 2013; Accepted: May 2, 2013

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as an 'Accepted Article', doi: 10.1002/eji.201343631.

Abstract

Vitamin A and its metabolite retinoic acid influence various aspects of immunity. Although the capacity of vitamin A to condition intestinal CD103⁺ dendritic cells (DCs) to imprint tissue-specific homing programs onto activated lymphocytes is well documented, it is unclear whether vitamin A also regulates DC populations in other tissues. A study published in this issue of the *European Journal of Immunology* [Eur. J. Immunol. 2013. 43: XXXX-XXXX] now demonstrates that vitamin A exerts profound effects on the subset composition of splenic DCs. By resolving that splenic ESAM^{hi} CD11b^{hi} DCs are preferentially responsive to regulation by vitamin A, these novel insights not only further support the notion that ESAM expression marks two distinct lineages of splenic CD11b^{hi} DCs, but also provide an important extension to our understanding of how vitamin A influences the immune system.

Dendritic cells (DCs) are rare, but widely distributed cells of hematopoietic origin that are specialized in capturing and presenting antigen to naïve T cells. Notably, DCs are comprised of multiple subsets that not only differ in phenotype and anatomical location, but, importantly, also exert distinct biological functions [1-3]. A useful strategy to divide these different subsets takes into consideration their relative ability to promote T-cell responses. In mice, surface expression of CD8 α identifies DCs with a superior ability to stimulate CD8⁺ T-cell responses, a process that often utilizes the cross-presentation pathway [4]. The appreciation that tissue-derived CD103⁺ DCs in mice, and BDCA3^{hi} DCs in humans, appear to be functionally and developmentally very closely related to CD8⁺ DCs, but do not express CD8, has recently lead to the proposal to define this lineage of DCs by their expression of XCR1 [5, 6], a chemokine receptor that is conserved between the different DC subsets and across the species. In addition to this proposed DC lineage, DCs expressing high levels of surface CD11b appear to be functionally biased towards promoting MHC class II-restricted CD4⁺ T-cell responses [7]. However, only a proportion of splenic CD11b^{hi} DCs express CD4, and tissue-resident CD11b^{hi} DCs are characterized by CD205 expression rather than CD4 [8]. Consequently, the cohort of CD11b^{hi} DCs appears considerably more heterogeneous compared with the relatively well-defined CD8⁺/XCR1⁺ lineage [4, 9]. This view is supported by the diverse range of transcription factors and molecules that have been implicated in the development of CD11b^{hi} DCs [10]. Interestingly, it was recently shown that differential requirement for Notch 2 receptor signaling defines two distinct lineages within the CD11b^{hi} DC population [11]. The Notch 2 receptor signaling-dependent CD11b^{hi} DC population is characterized by high-level expression of ESAM, an immunoglobulin superfamily molecule previously associated with neutrophil extravasation [12], and ESAM^{hi} CD11b^{hi} DC have been described as potent inducers of CD4⁺ T-cell priming [11]. Conversely, ESAM^{lo} CD11b^{hi} DCs develop independently of Notch 2 receptor signaling and have a gene

expression signature resembling that of monocytes [11]. However, exactly how ESAM^{hi} and ESAM^{lo} CD11b^{hi} DCs diverge during development and what factors control Notch 2 receptor signaling in CD11b^{hi} DCs remains obscure.

In this issue of the *European Journal of Immunology*, Beijer et al. [13] have described an unexpected role for vitamin A in promoting the development of these newly described ESAM^{hi} CD11b^{hi} DCs within the spleen. Vitamin A, or retinol, is acquired through dietary intake and stored predominantly within the liver before release into the circulation. Upon conversion of circulating vitamin A into its active metabolite retinoic acid (RA) by retinaldehyde dehydrogenase (Raldh), RA acts as a transcriptional regulator, binding retinoic acid receptors (RAR) and retinoic X receptors (RXR) that are located in the nucleus. The binding of RA to RAR/RXR heterodimers facilitates the recruitment of co-activators and the formation of transcriptional complexes that dock onto RA response elements within the regulatory regions of target genes, which in turn initiates transcription [14]. Vitamin A has long been appreciated for its essential role in host immunity, and more recently has gained considerable attention as a major player in controlling intestinal immunity [15]. In this case, vitamin A functions in a feedback loop, whereby locally produced RA conditions intestinal CD103⁺ DCs to upregulate the enzymes involved in vitamin A metabolism. Consequently, upon migrating into the intestinal lymph nodes, CD103⁺ DCs produce RA, which in turn drives the expression of gut-specific homing receptors (CCR9 and $\alpha_4\beta_7$) by activated T and B cells [16, 17]. However, while RA is now well accepted to condition DCs within the intestine, its contribution to DC development elsewhere in the body is not yet fully resolved.

Given this association with intestinal immunity, Beijer et al. [13] set out to examine whether vitamin A influences the splenic DC composition and made the intriguing discovery that,

relative to splenic CD8⁺ DCs (CD11b^{lo}CD4⁻CD8^{hi}), splenic CD4⁺ DCs (CD11b^{hi}CD4^{hi}CD8⁻) and splenic DN DCs (CD11b^{hi}CD4⁻CD8⁻) have elevated expression of a number of RA target genes (*MMP9*, *gp91hox* and *TG2*). It was also observed that CD4⁺ DCs and DN DCs express gene signatures indicative of preferential RA metabolism and utilization. To determine whether these RA responsive elements in CD4⁺ DCs and DN DCs reflect developmental or functional dependencies on vitamin A, the authors fed new-born mice (day 7.5-10 of gestation) a vitamin A-deficient diet and analyzed the relative proportion of the three DC subsets in the spleen after at least 9 weeks of diet. Strikingly, while the relative proportion of CD8⁺ DCs remained unaffected by the absence of RA, there was a significant reduction in the proportion of both CD4⁺ DCs and DN DCs. Collectively; this suggests that in contrast to CD8⁺ DCs, CD11b^{hi} DCs are subject to RA signaling and that these signaling events are necessary for their differentiation within the spleen. To further probe the activity of RA in shaping the differentiation of splenic DCs, Beijer et al. [13] performed the reverse experiment, placing mice on a RA-rich diet before examining the relative proportion of the three DC subsets in the spleen. Here, excessive RA resulted in a shift towards DN DCs. Specifically, the frequency of CD11b^{hi} DN DCs increased dramatically in the spleen, while the proportion of CD8⁺ DCs and, unexpectedly, CD4⁺ DCs was significantly suppressed in mice fed the vitamin A-rich diet. The lack of an increase in CD4⁺ DCs in response to RA overexposure and subtle, but significant differences in the expression patterns of some of the nuclear RA receptors (RXR α , RAR α , RXR β) between CD4⁺ DCs and DN DCs are likely related to heterogeneity within the CD11b^{hi} DC population. Indeed, when Beijer et al. [13] segregated CD11b^{hi} DCs on the basis of ESAM expression, which has recently been shown to resolve two distinct subsets within the CD11b^{hi} DC population [11], they noted that RA specifically affected ESAM^{hi} CD11b^{hi} DCs with this subset being selectively reduced in the absence of RA and increased upon overexposure to RA. The utilization of the well-established FMS-like

tyrosine kinase ligand (Flt3L) culture system, which allows the revisiting of key steps of splenic DC development in vitro [18], further substantiated these in vivo findings. Specifically, it was found that addition of RA during Flt3L-driven DC development skewed the culture drastically towards the SIRP α^{hi} CD11b $^{\text{hi}}$ DC subtype, although it was not examined whether ESAM was also expressed under these conditions. Whether the concomitant reduction in the culture equivalents of the CD8 $^{\text{hi}}$ /XCR1 $^{\text{hi}}$ lineage (SIRP α^{lo} CD11b $^{\text{lo}}$), and the reduced proportion of CD8 $^+$ DCs in mice kept on a vitamin A-rich diet indicates that RA also actively represses the development of CD8 $^{\text{hi}}$ /XCR1 $^{\text{hi}}$ DCs is an exciting possibility that remains to be tested.

Taken together Beijer et al. [13] demonstrate that RA signaling is necessary for the development of the ESAM $^{\text{hi}}$ CD11b $^{\text{hi}}$ DC subset within the spleen. These insights bring into focus a number of questions. For example, at what developmental stage are DCs subjected to RA conditioning? In this regard, it is interesting to note that hematopoietic stem cells in the bone marrow are among the few leukocytes that produce RA [19]. Analogous to the exposure of CD103 $^+$ DCs to RA in the intestine rather than in lymphoid organs [15], it is possible that pre-DCs would be exposed to RA in the bone marrow prior to their migration towards the spleen (Fig. 1A). Given that the proportion of circulating pre-DCs was unaffected in the absence of vitamin A, such a conditioning effect of RA would have to be regulated at a qualitative level rather than simply by altering the precursor product relationship numerically. Nevertheless, whether these events take place at the pre-DC level in the bone marrow or occur in the spleen requires further investigation. Another consideration arising from these findings relates to the potential mechanism by which RA signaling promotes the development of ESAM $^{\text{hi}}$ CD11b $^{\text{hi}}$ DCs. Given that ESAM $^{\text{hi}}$ CD11b $^{\text{hi}}$ DC differentiation is dependent upon Notch 2 receptor signaling, an interesting explanation maybe linked to RA regulating the

expression of Notch 2 receptor and/or its ligands (Fig. 1B). Indeed, it has recently been demonstrated that *Raldh2*-deficient mice, which are unable to convert vitamin A to RA, have diminished Notch signaling in developing neural tissues [20]. Thus, it is possible that RA signaling directly drives the expression of Notch 2 receptor and/or the ligands, and in this fashion, is necessary for the development of ESAM^{hi} CD11b^{hi} DCs. It will be interesting to examine whether the RA-dependent DC subsets express differential levels of Notch 2 receptor relative to other DC subsets. Similarly, future studies should investigate whether the Notch 2 receptor and/or its ligands contain RA-responsive elements within their promoter regions and are thereby directly regulated by RA. An alternative, although not mutually exclusive, mechanistic explanation may be that RA conditions pre-DCs to localize to distinct areas within the spleen that favour the differentiation of ESAM^{hi} CD11b^{hi} DCs (Fig. 1B). Since RA is well known to regulate homing receptor expression and migratory patterns of cells [21], it is conceivable that RA-conditioned DCs may preferentially migrate to regions of the spleen that are rich in Notch 2 receptor ligands, such as the marginal zone [22]. Stimulation of the Notch 2 receptor pathway could then promote ESAM^{hi} DC differentiation locally. It is interesting to contemplate this issue in light of the very recent finding that the chemokine receptor EBI2 (GPR183) and its ligand 7 α ,25-dihydroxycholesterol are critical for the positioning of CD4-expressing CD11b^{hi} DCs in the spleen [23]. Finally, as the observations by Beijer et al. were focussed on the spleen, it will be important to examine whether CD11b^{hi} DCs in the lymph nodes or tissues, such as dermal DCs or interstitial DCs, differentiate with comparable requirements for vitamin A and RA.

While the mode-of-action remains to be further defined, the findings of Beijer et al. [13] presented within this issue of the *European Journal of Immunology* clearly highlight a previously unappreciated role for RA signaling in regulating the diversity of splenic DCs.

Thus, vitamin A appears to play an ever-growing role in DC development, acting in both the intestinal and splenic compartment.

Acknowledgments

The authors would like to thank Dr. Ken Shortman (Walter and Eliza Hall Institute of Medical Research) for insightful discussions and sharing of unpublished data. ATS and SB are both supported by the National Health and Medical Research Council of Australia.

Conflict of interest

The authors declare no financial or commercial conflict of interest.

References

- 1 **Shortman, K. and Naik, S. H.**, Steady-state and inflammatory dendritic-cell development. *Nat. Rev. Immunol.* 2007. **7**: 19-30.
- 2 **Steinman, R. M.**, Decisions about dendritic cells: past, present, and future. *Annu Rev Immunol* 2012. **30**: 1-22.
- 3 **Merad, M., Sathé, P., Helft, J., Miller, J. and Mortha, A.**, The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. *Annu. Rev. Immunol.* 2013. **31**: 563-604.
- 4 **Shortman, K. and Heath, W. R.**, The CD8⁺ dendritic cell subset. *Immunol. Rev.* 2010. **234**: 18-31.
- 5 **Crozat, K., Guiton, R., Contreras, V., Feuillet, V., Dutertre, C. A., Ventre, E., Vu Manh, T. P. et al.**, The XC chemokine receptor 1 is a conserved selective marker of mammalian cells homologous to mouse CD8 α ⁺ dendritic cells. *J. Exp. Med.* 2010. **207**: 1283-1292.
- 6 **Bachem, A., Guttler, S., Hartung, E., Ebstein, F., Schaefer, M., Tannert, A., Salama, A. et al.**, Superior antigen cross-presentation and XCR1 expression define human CD11c⁺CD141⁺ cells as homologues of mouse CD8⁺ dendritic cells. *J. Exp. Med.* 2010. **207**: 1273-1281.
- 7 **Dudziak, D., Kamphorst, A. O., Heidkamp, G. F., Buchholz, V. R., Trumpfheller, C., Yamazaki, S., Cheong, C. et al.**, Differential antigen processing by dendritic cell subsets in vivo. *Science* 2007. **315**: 107-111.
- 8 **Henri, S., Guilliams, M., Poulin, L. F., Tamoutounour, S., Ardouin, L., Dalod, M. and Malissen, B.**, Disentangling the complexity of the skin dendritic cell network. *Immunol. Cell. Biol.* 2010. **88**: 366-375.
- 9 **Bedoui, S., Prato, S., Mintern, J., Gebhardt, T., Zhan, Y., Lew, A. M., Heath, W. R. et al.**, Characterization of an immediate splenic precursor of CD8⁺ dendritic cells capable of inducing antiviral T cell responses. *J. Immunol.* 2009. **182**: 4200-4207.
- 10 **Belz, G. T. and Nutt, S. L.**, Transcriptional programming of the dendritic cell network. *Nat. Rev. Immunol.* 2012. **12**: 101-113.

- 11 **Lewis, K. L., Caton, M. L., Bogunovic, M., Greter, M., Grajkowska, L. T., Ng, D.,**
Klinakis, A. et al., Notch2 receptor signaling controls functional differentiation of
dendritic cells in the spleen and intestine. *Immunity* 2011. **35**: 780-791.
- 12 **Wegmann, F., Petri, B., Khandoga, A. G., Moser, C., Khandoga, A., Volkery, S.,**
Li, H. et al., ESAM supports neutrophil extravasation, activation of Rho, and VEGF-
induced vascular permeability. *J. Exp. Med.* 2006. **203**: 1671-1677.
- 13 **Beijer, M. R., Molenaar, R., Goverse, G., Mebius, R. E., Kraal, G., den Haan, J.**
M., A crucial role for retinoic acid in the development of Notch-dependent murine
splenic CD8⁻CD4⁻ and CD4⁺ dendritic cells. *Eur. J. Immunol.* 2013. **43**.
- 14 **Blomhoff, R. and Blomhoff, H. K.,** Overview of retinoid metabolism and function. *J.*
Neurobiol. 2006. **66**: 606-630.
- 15 **Stock, A., Napolitani, G. and Cerundolo, V.,** Intestinal DC in migrational
imprinting of immune cells. *Immunol. Cell. Biol.* 2013. **91**: 240-249.
- 16 **Campbell, D. J. and Butcher, E. C.,** Rapid acquisition of tissue-specific homing
phenotypes by CD4(+) T cells activated in cutaneous or mucosal lymphoid tissues. *J.*
Exp. Med. 2002. **195**: 135-141.
- 17 **Mora, J. R., Iwata, M., Eksteen, B., Song, S. Y., Junt, T., Senman, B., Otipoby, K.**
L. et al., Generation of gut-homing IgA-secreting B cells by intestinal dendritic cells.
Science 2006. **314**: 1157-1160.
- 18 **Naik, S. H., Proietto, A. I., Wilson, N. S., Dakic, A., Schnorrer, P., Fuchsberger,**
M., Lahoud, M. H. et al., Cutting edge: generation of splenic CD8⁺ and CD8⁻
dendritic cell equivalents in Fms-like tyrosine kinase 3 ligand bone marrow cultures. *J.*
Immunol. 2005. **174**: 6592-6597.
- 19 **Storms, R. W., Trujillo, A. P., Springer, J. B., Shah, L., Colvin, O. M., Ludeman,**
S. M. and Smith, C., Isolation of primitive human hematopoietic progenitors on the
basis of aldehyde dehydrogenase activity. *Proc. Natl. Acad. Sci. U S A* 1999. **96**:
9118-9123.
- 20 **Paschaki, M., Lin, S. C., Wong, R. L., Finnell, R. H., Dolle, P. and Niederreither,**
K., Retinoic acid-dependent signaling pathways and lineage events in the developing
mouse spinal cord. *PLoS One* 2012. **7**: e32447.
- 21 **Iwata, M., Hirakiyama, A., Eshima, Y., Kagechika, H., Kato, C. and Song, S. Y.,**
Retinoic acid imprints gut-homing specificity on T cells. *Immunity* 2004. **21**: 527-538.
- 22 **Tan, J. B., Xu, K., Cretegnny, K., Visan, I., Yuan, J. S., Egan, S. E. and Guidos, C.**
J., Lunatic and manic fringe cooperatively enhance marginal zone B cell precursor
competition for delta-like 1 in splenic endothelial niches. *Immunity* 2009. **30**: 254-263.
- 23 **Gatto, D., Wood, K., Caminschi, I., Murphy-Durland, D., Schofield, P., Christ,**
D., Karupiah, G. et al., The chemotactic receptor EBI2 regulates the homeostasis,
localization and immunological function of splenic dendritic cells. *Nat. Immunol.*
2013.

See accompanying article:

<http://dx.doi.org/10.1002/eji.201243218>

Figure 1. Retinoic acid (RA) drives ESAM^{hi} CD11b^{hi} DC differentiation.

(A) Pre-DCs seeding the spleen give rise to heterogeneous populations of DCs that can be roughly divided into the XCR1⁺/CD8⁺ DCs and CD11b^{hi} DCs. In this issue of the *European Journal of Immunology*, Beijer et al. [13] describe that vitamin A-derived RA promotes the differentiation of a subset of CD11b^{hi} DCs that is characterized by the expression of ESAM. These findings not only uncover a novel link between vitamin A and splenic DC differentiation, but also raise some interesting questions. For example, is the bias in the ability of RA to drive the differentiation of ESAM^{hi} CD11b^{hi} DC accompanied by active suppression of the XCR1⁺/CD8⁺ DC lineage? (B) Moreover, with RA linked to regulating the responsiveness of some cells to Notch ligands [20], and Notch 2 receptor expression required for the differentiation of ESAM^{hi} CD11b^{hi} DCs [11], is Notch signaling in DCs subject to regulation by RA? Finally, given the existence of Notch ligand gradients within the spleen [22], and the recent appreciation that the local splenic microenvironment influences CD11b^{hi} DC development [23], does RA affect splenic DC differentiation by impacting on their local distribution in the spleen?

